Multiomic Health

AI-ENABLED PRECISION MEDICINE FOR METABOLIC-SYNDROME-RELATED CONDITIONS

ABOUT.

Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden. With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.

Metabolic syndrome, a cluster of closely-related diseases (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease, non-alcoholic fatty liver) with many common risk factors, is costing the healthcare system $2 trillion (forecast >$5.5 trillion by 2040). It is a 1.6x larger market than oncology, yet attracts only 40% of the VC dollars.

TYPE 2
DIABETES

CHRONIC KIDNEY DISEASE

ATHEROSCLEROSIS

NON-ALCOHOLIC FATTY LIVER

OUR FOCUS.

A major unmet need is the lack of high-fidelity tools to focus the right treatments on the right patients. In oncology, treatments are personalized based on genetic and protein biomarkers whereas metabolic syndrome patients are being prescribed drugs based on their blood pressure, fasting glucose and cholesterol levels. As metabolic syndrome is a complex multifactorial condition, it requires systems medicine models and composite biomarkers that were hitherto infeasible. ML-enabled data science and rapidly-falling omics costs have changed the game and we are aiming at becoming the leader in this space

STATISTICS.

METABOLIC SYNDROME PANDEMIC

cause of death globally - 45% of all deaths result from metabolic syndrome conditions

adults are affected by metabolic syndrome worldwide

CHILDREN AND ADOLESCENTS EVENTUALLY TO DEVELOP METABOLIC SYNDROME

$tn

global healthcare cost burden of metabolic syndrome conditions

please view sidebar for data sources.

WHAT WE DO

MULTI Omic ANalysis.

UNDERSTANDING CHRONIC DISEASE BIOLOGY

EXPERTS IN THEIR FIELDS

OPERATING TEAM.

Robert Thong

Co-founder & CEO

30+ years in biopharma & healthcare, focusing on R&D management, B2B partnerships and value creation strategy. Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models

Ariella Cohain

CHIEF TECHNOLOGY OFFICER

Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion

Slaven Stekovic

CHIEF SCIENCE OFFICER

Forbes 30 under 30. Founded The Longevity Labs, whose nutraceutical is now marketed in >14 countries including USA, exited after 3 years. Leadership experience with two other startups in cancer genomics and AI-enabled robotics.

Celia Antonio Schell

VP STUDY & PARTNERSHIP OPERATIONS

14 years experience in clinical research at Novartis and ICON. Recently managed a global Phase III clinical trial of >7,000 cardiovascular patients across 43 countries.

Andrew Parton

Lead DATA SCIENTIST

Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research including journal papers on systems biology modeling of atherosclerosis.

Esra Berkol

CHIEF OF STAFF & FINANCE MANAGER

Broad experience base of international collaborative activities. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Founded & exited own business.

Karina Close

SENIOR BIOINFORMATICIAN

Experienced at analyzing and interpreting multi-omic patient and in vitro/in vivo data. Previously in the translational medicine data science team at Benevolent AI.

Becky Cripps

BUSINESS DEVT. & ALLIANCE MGMT.

Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations

Henrietta Bull

PARTNERSHIPS & CORPORATE DEVT.

Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D

Heather Jackson

BIOINFORMATICIAN

Experienced at analyzing high-dimensional omics datasets and building bioinformatics pipelines. Previously a postdoc at Imperial College London.

Laura Mitchell

SCIENCE & BUSINESS ANALYST

Previously interned at Immunocore, AstraZeneca and the Wellcome Sanger Institute.